Approved GLP-1 RAs: Indications and Administration Dulaglutide (Trulicity) (injection weekly) Type 2 Diabetes Exenatide extended-release (Bydureon bcise) (injection weekly) Type 2 Diabetes Exenatide (Byetta) (injection twice daily) Type 2 Diabetes Semaglutide (Ozempic) (injection weekly) Type 2 Diabetes Liraglutide (Victoza, Saxenda) (injection daily) Obesity and Type 2 Diabetes, Respectively Lixisenatide (Adlyxin) (injection daily) Type 2 Diabetes Semaglutide (Rybelsus) (taken by mouth once daily) Obesity Semaglutide (Wegovy) (injection weekly) Obesity Tirzepatide* (Mounjaro, Zepbound)(injection weekly) Type 2 Diabetes and Obesity, Respectively View the FDAs up-to-date list of approved GLP-1 RAs Cardiovascular Risk Reduction Benefits of GLP-1 RAs for Patients with T2D 2 to 4 times more likely to develop cardiovascular disease (CVD) than those without T2D
Investigating the association between GLP-1 receptor agonists and mood disorders: a study integrating real-world data and Mendelian randomization
Are palpitations dangerous on Ozempic
Additionally, retinol can help unclog pores, making it an effective treatment for acne and preventing future breakouts
It doesn't enhance T-cell function, antibody production, or antiviral defense the way Thymosin Alpha-1 does
Ozempic and Mounjaro are not currently approved for this age group
